Overview:

Summary

“Vertex’s VX770 Is Poised To Become The First Targeted Therapy To Be Approved In Cystic Fibrosis” provides key information on current available treatment of Cystic Fibrosis and importance Vertex’s VX770 as a target therapy in Cystic Fibrosis market.

Scope

- Data and information on role of newer VEGF Inhibitors in Cystic Fibrosis

Reasons to buy

- Develop business strategies by understanding the trends and developments in Cystic Fibrosis Market

1 Table of Contents 1
2 Summary 1
3 Cystic Fibrosis Overview 1
3.1 Disease Overview 1
3.2 Epidemiology 2
3.3 Survival rates 2
3.4 Current Therapy Options 2
3.5 Unmet Need 2
3.6 Drivers and Barriers 2
3.6.1 Drivers 2
3.6.2 Barriers 2
3.7 VX-770 – First Novel Targeted Therapy for Cystic Fibrosis 3
3.8 STRIVE Clinical Trial Details 3
3.9 Cytic Fibrosis Market 3
4 Appendix 3
4.1 Methodology 3
4.1.1 Coverage 3
4.1.2 Secondary Research 4
4.1.3 Primary Research 4
4.1.4 Expert Panel Validation 4
4.2 Contact Us 4
4.3 Disclaimer 4